NCT03882008View on ClinicalTrials.gov

A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid Arthritis

PHASE4CompletedINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

May 23, 2019

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Abatacept

All the subjects will receive Abatacept subcutaneous injection once a week for 24 weeks

Trial Locations (1)

98195

University of Washington, Seattle

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University of Washington

OTHER